These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28627426)

  • 1. Neurodegenerative signaling factors and mechanisms in Parkinson's pathology.
    Goswami P; Joshi N; Singh S
    Toxicol In Vitro; 2017 Sep; 43():104-112. PubMed ID: 28627426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease.
    Thomas B; Beal MF
    Hum Mol Genet; 2007 Oct; 16 Spec No. 2():R183-94. PubMed ID: 17911161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease: Mechanisms, translational models and management strategies.
    Raza C; Anjum R; Shakeel NUA
    Life Sci; 2019 Jun; 226():77-90. PubMed ID: 30980848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease.
    Miyazaki I; Asanuma M
    Curr Pharm Des; 2017; 23(33):4936-4947. PubMed ID: 28699520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parkinson's disease: Autoimmunity and neuroinflammation.
    De Virgilio A; Greco A; Fabbrini G; Inghilleri M; Rizzo MI; Gallo A; Conte M; Rosato C; Ciniglio Appiani M; de Vincentiis M
    Autoimmun Rev; 2016 Oct; 15(10):1005-11. PubMed ID: 27497913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
    Liu L; Peritore C; Ginsberg J; Shih J; Arun S; Donmez G
    Behav Brain Res; 2015 Mar; 281():215-21. PubMed ID: 25541039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathogenesis, experimental models and new therapeutic strategies for Parkinson's disease.
    Yamashita H; Matsumoto M
    Regen Med; 2007 Jul; 2(4):447-55. PubMed ID: 17635051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin in Parkinson's disease.
    Politis M; Niccolini F
    Behav Brain Res; 2015 Jan; 277():136-45. PubMed ID: 25086269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives.
    Sarkar S; Raymick J; Imam S
    Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutathione--a review on its role and significance in Parkinson's disease.
    Martin HL; Teismann P
    FASEB J; 2009 Oct; 23(10):3263-72. PubMed ID: 19542204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SUMO-regulated mitochondrial function in Parkinson's disease.
    Guerra de Souza AC; Prediger RD; Cimarosti H
    J Neurochem; 2016 Jun; 137(5):673-86. PubMed ID: 26932327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal hippocampal neurogenesis in Parkinson's disease: relevance to a new therapeutic target for depression with Parkinson's disease.
    Lim J; Bang Y; Choi HJ
    Arch Pharm Res; 2018 Oct; 41(10):943-954. PubMed ID: 30136247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current insights into pathogenesis of Parkinson's disease: Approach to mevalonate pathway and protective role of statins.
    Saeedi Saravi SS; Saeedi Saravi SS; Khoshbin K; Dehpour AR
    Biomed Pharmacother; 2017 Jun; 90():724-730. PubMed ID: 28419968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heredity in Parkinson's disease: new findings.
    Lev N; Melamed E
    Isr Med Assoc J; 2001 Jun; 3(6):435-8. PubMed ID: 11433638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic potential of neurotrophic factors in the treatment of Parkinson's disease.
    Lindsay RM; Altar CA; Cedarbaum JM; Hyman C; Wiegand SJ
    Exp Neurol; 1993 Nov; 124(1):103-18. PubMed ID: 8282068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin 1A Receptors on Astrocytes as a Potential Target for the Treatment of Parkinson's Disease.
    Miyazaki I; Asanuma M
    Curr Med Chem; 2016; 23(7):686-700. PubMed ID: 26795196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Damage to dopaminergic neurons is mediated by proliferating cell nuclear antigen through the p53 pathway under conditions of oxidative stress in a cell model of Parkinson's disease.
    Li DW; Li GR; Zhang BL; Feng JJ; Zhao H
    Int J Mol Med; 2016 Feb; 37(2):429-35. PubMed ID: 26677001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The role of estrogens in Parkinson's disease].
    Dziedziejko V; Białecka M; Machoy-Mokrzyńska A; Kłodowska-Duda G; Chlubek D
    Postepy Hig Med Dosw (Online); 2009 Dec; 63():627-33. PubMed ID: 20097949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advantages of Vasoactive Intestinal Peptide for the Future Treatment of Parkinson's Disease.
    Korkmaz OT; Tunçel N
    Curr Pharm Des; 2018; 24(39):4693-4701. PubMed ID: 30636594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bee venom for the treatment of Parkinson's disease: How far is it possible?
    Awad K; Abushouk AI; AbdelKarim AH; Mohammed M; Negida A; Shalash AS
    Biomed Pharmacother; 2017 Jul; 91():295-302. PubMed ID: 28477460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.